GoldenGolden
Advanced Search
Aduro Biotech

Aduro Biotech

Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases.

Timeline

April 2015
Aduro Biotech raises a $25,000,000 venture round from Novartis.
January 2015
Aduro Biotech raises a $51,400,000 series D round from Clough Capital Partners, Fidelity Investments, Foresite Capital, Franklin Advisors, Janus Capital Group, Jennison Associates, Morningside Group and OrbiMed.
June 2014
Aduro Biotech raises a $55,700,000 series C round from Johnson & Johnson Development Corporation and Morningside Group.
December 2013
Aduro Biotech raises a $512,100 venture round.
September 2013
Aduro Biotech raises a $13,000,000 convertible note.
January 2013
Aduro Biotech raises a $9,000,000 series B round.
June 13, 2011
Aduro Biotech was founded.
April 20, 2011
Aduro Biotech raises a $19,250,000 series B round from Morningside Group.
November 2009
Aduro Biotech raises a $1,200,000 venture round.
December 2008
Aduro Biotech raises a $1,800,000 convertible note.

Funding rounds

SBA Awards

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 5, 2021
BioSpace
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa
Arlene Weintraub
January 4, 2021
FierceBiotech
Activating the immune pathway STING creates an inflammatory environment that should improve immuno-oncology treatments, but clinical trials have been disappointing so far. A University of North Carolina team has promising evidence that combining CAR-T cells with STING agonists could be effective in solid tumors.
BioSpace
June 2, 2020
BioSpace
BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of doses Pharmacokinetics (PK) of BION-1301 were generally dose-proportional with an estimated half-life of 33 days, suggesting the potential for monthly dosing BION-1301 dose-dependently and durably reduced IgA and IgM, and to a lesser extent, IgG, providing a pharmacodynamic (PD) window to potentially exploit reductions in IgA while
BioSpace
June 2, 2020
BioSpace
- Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy - Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook's Existing Investors - Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months - Companies to H

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.